Interferon-α as maintenance therapy can significantly reduce relapse in patients with favorable-risk acute myeloid leukemia.

Abstract

To evaluate the efficacy of interferon-α (IFN-α) as maintenance therapy in patients with favorable-risk acute myeloid leukemia (AML), this retrospective study enrolled 84 patients with favorable-risk AML: 42 patients who received IFN-α maintenance therapy and 42 patients who did not (control). The median follow-up time and duration of IFN-α treatment was 26 (6-54) months and 18 (2-24) months, respectively. The 4-year estimated relapse-free survival (RFS) after the last consolidation chemotherapy was 86.8% (95% confidence interval (CI), 75.8-97.8%) in the IFN-α group and 55.7% (95% CI, 37.2-74.3%) in the control group (p=.007). The 4-year estimated overall survival was 94.4% (95% CI, 86.8-102%) and 76.4% (95% CI, 61.9-90.9%) in IFN-α and control groups, respectively (p=.040). The Cox regression analysis showed that IFN-α treatment was the only independent factor affecting RFS (p=.004). Maintenance therapy with IFN-α may prevent relapse in favorable-risk AML after consolidation chemotherapy.

• Authors: Hao Jiang, Xiao-Hong Liu, Jun Kong, Jing Wang, Jin-Song Jia, Sheng-Ye Lu, Li-Zhong Gong, Xiao-Su Zhao, Qian Jiang, Ying-Jun Chang, Yu Wang, Guo-Rui Ruan, Ya-Zhen Qin, Kai-Yan Liu, Xiao-Jun Huang
• Journal: Leukemia & lymphoma (Leuk Lymphoma) Vol. 62 Issue 12 Pg. 2949-2956 (12 2021) ISSN: 1029-2403 [Electronic] United States
• PMID: 34196252 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Interferon-alpha

Topics

• Consolidation Chemotherapy
• Disease-Free Survival
• Humans
• Interferon-alpha (therapeutic use)
• Leukemia, Myeloid, Acute (diagnosis, drug therapy)
• Recurrence
• Retrospective Studies